TUBB3 and neoplasm: TUBB3 negativity, a marker of taxane response,26, 27, 28 was associated with MSI‐H, whereas negativity (taxane resistance) was related to PD‐L1 in many tumor types; thus, the benefit for combining taxanes with immunotherapy is likely to be more frequent in patients with MSI‐H and less frequent in those with PD‐L1 expression (Table 3).